Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 34.

Hirschmann, A; Lupatsch, J E; Schwenkglenks, M; Panje, C M; Matter-Walstra, K; Espeli, V; Dedes, K J; Siano, M (2018). Cost-effectiveness of nivolumab in the treatment of head and neck cancer. Oral Oncology, 87:104-110.

Dedes, K J. Synthetic lethality of PARP-inhibition for non-BRCA1/2-mutated gynecological cancers. 2018, University of Zurich, Faculty of Medicine.

Matter-Walstra, K; Schwenkglenks, Matthias; Dedes, K J (2017). Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting. Breast Cancer Research and Treatment, 163(3):635.

Matter-Walstra, Klazien; Ruhstaller, T; Klingbiel, D; Schwenkglenks, Matthias; Dedes, K J (2016). Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Breast Cancer Research and Treatment, 158(1):51-57.

Leimbacher, B; Samartzis, N; Imesch, P; Dedes, K J; Fink, D; Canonica, C (2012). Inpatient and outpatient loop electrosurgery excision procedure for cervical intraepithelial neoplasia: a retrospective analysis. Archives of Gynecology and Obstetrics, 285(5):1441-1445.

Church, D N; Koppensteiner, R; Yap, T; Fink, Daniel; Dedes, K J (2012). P13K-AKT-mTOR inhibitors for the systematic treatment of endometrial cancer. Expert Review of Obstetrics & Gynecology, 7(5):421-430.

Dedes, K J; Fink, Daniel; Steiner, R A (2012). Principes de la chimiothérapie. In: Hornung, R; Fink, Daniel. Traitement de deuxième intention du cancer du sein. Bremen: UNI-MED Verlag, 50-54.

Dedes, K J; Natrajan, R; Lambros, M B; Geyer, F C; Lopez-Garcia, M A; Savage, K; Jones, R L; Reis-Filho, J S (2011). Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer. European Journal of Cancer, 47(1):138-150.

Dedes, K J; Wetterskog, D; Ashworth, A; Kaye, S B; Reis-Filho, J S (2011). Emerging therapeutic targets in endometrial cancer. Nature Reviews. Clinical Oncology, 8(5):261-271.

Samartzis, N; Imesch, P; Dedes, K J; Samartzis, E P; Fedier, A; Fink, D; Caduff, R; Fehr, M K (2011). Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: A tissue microarray study. BMC Cancer, 11:463.

Wilkerson, P M; Dedes, K J; Wetterskog, D; Mackay, A; Lambros, M B; Mansour, M; Frankum, J; Lord, C J; Natrajan, R; Ashworth, A; Reis-Filho, J S (2011). Functional characterization of EMSY gene amplification in human cancers. Journal of Pathology, 225(1):29-42.

Brough, R; Frankum, J R; Sims, D; Mackay, A; Mendes-Pereira, A M; Bajrami, I; Costa-Cabral, S; Rafiq, R; Ahmad, A S; Cerone, M A; Natrajan, R; Sharpe, R; Shiu, K K; Wetterskog, D; Dedes, K J; Lambros, M B; Rawjee, T; Linardopoulos, S; Reis-Filho, J S; Turner, N C; Lord, C J; Ashworth, A (2011). Functional viability profiles of breast cancer. Cancer Discovery, 1(3):260-273.

Dedes, K J; Fink, D (2011). Ovarial-, Zervix- und Vulvakarzinom: Neues zu gynäkologischen Tumoren. Hausarzt Praxis, 8(15):15-18.

Papadatos-Pastos, D; Dedes, K J; de Bono, J S; Kaye, S B (2011). Revisiting the role of antiandrogen strategies in ovarian cancer. The Oncologist, 16(10):1413-1421.

Dedes, K J; Wilkerson, P M; Wetterskog, D; Weigelt, B; Ashworth, A; Reis-Filho, J S (2011). Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle, 10(8):1192-1199.

Dedes, K J; Fink, D; Steiner, R (2011). Systemische Tumorkontrolle: Chemotherapeutische Prinzipien. In: Hornung, R; Fink, D. Zweitlinientherapie des Mammakarzinoms. Bremen, DE: UNI-MED Verlag, 47-52.

Forster, M D; Dedes, K J; Sandhu, S; Frentzas, S; Kristeleit, R; Ashworth, A; Poole, C J; Weigelt, B; Kaye, S B; Rhoda Molife, L (2011). Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nature Reviews. Clinical Oncology, 8(5):302-306.

Dedes, K J; Lopez-Garcia, M A; Geyer, F C; Lambros, M B K; Savage, K; Vatcheva, R; Wilkerson, P; Wetterskog, D; Lacroix-Triki, M; Natrajan, R; Reis-Filho, J S (2010). Cortactin gene amplification and expression in breast cancer: a chromogenic in situ hybridisation and immunohistochemical study. Breast Cancer Research and Treatment, 124(3):653-666.

Blank, P R; Dedes, K J; Szucs, T D (2010). Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. PharmacoEconomics, 28(8):629-647.

Lambros, M B; Natrajan, R; Geyer, F C; Lopez-Garcia, M A; Dedes, K J; Savage, K; Lacroix-Triki, M; Jones, R L; Lord, C J; Linardopoulos, S; Ashworth, A; Reis-Filho, J S (2010). PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study. Modern Pathology, 23(10):1334-1345.

Dedes, K J; Wetterskog, D; Mendes-Pereira, A M; Natrajan, R; Lambros, M B; Geyer, F C; Vatcheva, R; Savage, K; Mackay, A; Lord, C J; Ashworth, A; Reis-Filho, J S (2010). PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Science Translational Medicine, 2(53):53ra75.

Matter-Walstra, K W; Dedes, K J; Schwenkglenks, M; Brauchli, P; Szucs, T D; Pestalozzi, B C (2010). Trastuzumab beyond progression: a cost-utility analysis. Annals of Oncology, 21(11):2161-2168.

Dedes, K J; Dedes, I; Imesch, P; von Bueren, A O; Fink, D; Fedier, A (2009). Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anti-Cancer Drugs, 20(5):321-333.

Dedes, K J; Matter-Walstra, K; Schwenkglenks, M; Pestalozzi, B C; Fink, D; Brauchli, P; Szucs, T D (2009). Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. European Journal of Cancer, 45(8):1397-1406.

Müller, M K; Dedes, K J; Dindo, D; Steiner, S; Hahnloser, D; Clavien, P A (2009). Impact of clinical pathways in surgery. Langenbeck's Archives of Surgery, 394(1):31-39.

Dedes, K J; Fink, D (2009). Clinical Presentation and Surgical Management of Invasive Lobular Carcinoma of the Breast. Breast Disease, 30:31-37.

Imesch, P; Dedes, K J; Furlato, M; Fink, D; Fedier, A (2009). MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. International Journal of Oncology, 35(3):631-640.

Szucs, T D; Largeron, N; Dedes, K J; Rafia, R; Bénard, S (2008). Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Current Medical Research and Opinion, 24(5):1473-1483.

Dedes, K J; Gabriel, N; Fink, D (2008). Aktuelle adjuvante endokrine Therapie des Mammakarzinoms. Gynäkologisch-geburtshilfliche Rundschau, 48(3):130-137.

Szucs, T D; Dedes, K J (2008). Balancing costs and benefits in cancer therapy and prevention. Annals of Oncology, 19(Suppl.):vii313-vii319.

Dedes, K J; Beneder, C; Samartzis, N; Muller, M D; Fink, D; Fehr, M K (2008). Outcome of treated anogenital intraepithelial neoplasia among human immunodeficiency virus-infected women. Journal of Reproductive Medicine, 53(12):947-951.

Dedes, K J; Szucs, T D; Imesch, P; Fedier, A; Fehr, M K; Fink, D (2007). Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Annals of Oncology, 18(9):1493-1499.

Dedes, K J; Bramkamp, M; Szucs, T D (2005). Paclitaxel: cost–effectiveness in ovarian cancer. Expert Review of Pharmacoeconomics and Outcomes Research, 5(3):235-243.

Bramkamp, M; Dedes, K J; Szucs, T D (2005). Pharmacotherapy of acute coronary syndromes: medical economics with an emphasis on clopidogrel. Cardiovascular Drugs and Therapy, 19(4):291-299.

This list was generated on Sun Jun 16 16:34:28 2019 CEST.